ABSTRACT
Background: Individual reports have described lymphoproliferative disorders (LPDs) and cutaneous lymphomas emerging after administration of the COVID-19 vaccine; however, the relationship between reactions and vaccine types has not yet been examined. Objective: Determine if there are cases of cutaneous LPDs associated with certain COVID-19 vaccines and their outcomes. Methods: We analysed PubMed, the Vaccine Adverse Events Reporting System (VAERS), and our database for instances of biopsy-proven LPDs following COVID-19 vaccines. Results: Fifty cases of biopsy-proven LPDs arising after COVID-19 vaccination were found: 37 from medical literature, 11 from VAERS and two from our institution. Geographical distribution revealed the most cases in the United States, Italy, and Greece, with single cases in Spain, Colombia, Canada, Japan, and Romania. The average age of patients was 53; with a slight male predominance (male-to-female ratio of 1.5:1). The Pfizer-BioNTech vaccine was associated with LPDs in 36/50 (72%) cases, aligning with its 70% share of the global vaccine market. Histopathology revealed CD30+ in 80% of cases. The most prevalent form of LPD was lymphomatoid papulosis (LyP, 30%). All reported cases produced favourable outcomes (either complete or near-complete remission). Therapeutic approaches ranged from observation to treatment with steroids, methotrexate, or excision. Conclusion: LPDs after COVID-19 vaccination appear in the context of the same vaccines (proportionally to their global market shares), share clinical and pathological findings, and have indolent, self-limited character.
ABSTRACT
Cutaneous squamous cell carcinoma in-situ (SCCis) is an intraepithelial tumor with a good prognosis. Standard treatment includes both surgical and non-surgical interventions. We determined the clearance rate for SCCis and residual SCCis identified on frozen section during Mohs micrographic surgery (MMS) after treatment with topical fluorouracil 5% cream (5-FU). All MMS cases were initiated for biopsy-proven invasive squamous cell carcinoma (SCC). A retrospective chart review was conducted from January 2017-February 2024 at Columbia University Irving Medical Center (CUIMC) to identify patients with SCCis who were treated with topical 5-FU as primary therapy or adjuvant therapy (AT) for residual SCCis post-MMS for invasive SCC. 41 patients were included (80% males, 70.1 ± 11.8 years). The average follow-up time for the primary therapy group was 25.4 ± 12.8 months, and for the post-MMS AT group 22.5 ± 11.1 months. In the group treated with topical 5-FU as primary therapy (n = 28), 27 patients (96.43%, 95% confidence interval: 81.65-99.91%) achieved complete clearance. One patient had recurrence at 8 months post-treatment. Of the patients in the post-MMS adjuvant treatment group (n = 13), 12 (92.3% clearance, 95% confidence interval 63.97-99.81%) achieved complete clearance. One patient had recurrence at 8 months post-treatment. This study found that topical 5-FU cream is effective as both primary therapy for SCCis and as adjuvant therapy for residual SCCis following MMS of invasive SCC.
Subject(s)
Carcinoma, Squamous Cell , Fluorouracil , Skin Neoplasms , Humans , Fluorouracil/administration & dosage , Fluorouracil/therapeutic use , Male , Female , Aged , Retrospective Studies , Middle Aged , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Skin Neoplasms/diagnosis , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/diagnosis , Chemotherapy, Adjuvant/methods , Aged, 80 and over , Treatment Outcome , Mohs Surgery , Antimetabolites, Antineoplastic/administration & dosage , Antimetabolites, Antineoplastic/therapeutic use , Carcinoma in Situ/drug therapy , Carcinoma in Situ/pathology , Administration, Topical , Follow-Up Studies , Neoplasm Recurrence, Local/prevention & control , Administration, CutaneousABSTRACT
Individual reports described lymphoproliferative disorders (LPDs) after COVID-19 vaccination; however, the relationship between cases is unexamined. We aim to determine if there are cases of cutaneous LPDs associated with COVID-19 vaccination and their outcomes. We present a review of world literature, vaccine registries, and two unreported cases of LPDs after COVID-19 vaccination. Review of the medical literature, VAERS, and our two cases reveal predominance of Pfizer-BioNTech vaccine, younger patients, and males. All cases resulted in favorable outcomes. Approximately 84% of cases demonstrated CD30+ positivity in their skin biopsies, suggesting that an antigenic trigger may lead to a type IV adaptive immune response, with clonal expansion of CD30+ T-cells and subsequent oncogenic mutational hits eventuating in transient LPDs. LPDs after COVID-19 vaccination appear in the context of the same vaccines (proportionally to their global market shares), share clinical and pathological findings, and have indolent, self-limited character.
Subject(s)
COVID-19 , Lymphomatoid Papulosis , Lymphoproliferative Disorders , Skin Diseases , Skin Neoplasms , Male , Humans , Skin Neoplasms/pathology , Lymphomatoid Papulosis/pathology , COVID-19 Vaccines/adverse effects , Ki-1 Antigen , COVID-19/prevention & control , Vaccination/adverse effects , Lymphoproliferative Disorders/pathologySubject(s)
Physicians , Plastic Surgery Procedures , Skin Neoplasms , Surgery, Plastic , Humans , Motivation , Skin Neoplasms/surgery , Mohs SurgerySubject(s)
Linear IgA Bullous Dermatosis , Stevens-Johnson Syndrome , Humans , Linear IgA Bullous Dermatosis/chemically induced , Linear IgA Bullous Dermatosis/diagnosis , Stevens-Johnson Syndrome/diagnosis , Stevens-Johnson Syndrome/etiology , Etanercept/adverse effects , Anti-Bacterial Agents/adverse effects , Vancomycin/adverse effects , Immunoglobulin AABSTRACT
Online reviews are the newest method for patients to evaluate their providers. However, insufficient studies focus on the role of inherent physician characteristics, such as gender and years of experience, on patient satisfaction. We analyzed both quantitative and qualitative online reviews of 350 general dermatology providers at 121 Accreditation Council for Graduate Medical Education-accredited dermatology programs across the country to determine the effect of gender and years of experience. There were 38,008 online reviews of general dermatology providers. There was no significant difference in male and female overall ratings. Ratings were overall equally positive for both genders. Female providers were more likely to have positive written comments regarding time spent with patients (P = 0.027). New providers received highest overall, promptness, and time spent with patient ratings (P < 0.001). Medium experience providers received highest scores in bedside manner (P < 0.001), accurate diagnosis (P = 0.018), and ability to answer questions (P = 0.005). Advanced providers scored the lowest across all categories. In conclusion, gender did not significantly affect ratings, although females received more positive written comments on time spent with patients. Years of experience, however, is a significant factor in patient ratings, with new or medium experience providers scoring higher than advanced providers in every category.
ABSTRACT
Measuring patient satisfaction of general dermatology providers is an important goal because it can lead to improved clinical outcomes. Online reviews are emerging as the newest forum for evaluating physicians in real time and provide a valuable tool for measuring patient satisfaction. We analyzed both quantitative and qualitative online reviews of general dermatology providers at 121 Accreditation Council for Graduate Medical Educationâaccredited dermatology programs across the country to determine which elements are most discussed in online ratings using the online platforms Vitals, US News, WebMD, Google Reviews, and Healthgrades. There were 38,008 online reviews included from general dermatology providers at Accreditation Council for Graduate Medical Educationâaccredited programs. The median average overall quantitative rating of providers was 4.35 of 5. There were more positive (77%) than negative (23%) comments. The overall ratings of general dermatology providers were favorable. The most influential factors in both positive and negative comments were patient's perceived experience and physician's bedside manner (26% and 17%, respectively). Less important factors included office space, treatment by auxiliary staff, wait time, costs, and time spent with patients. This suggests that a provider's personality, expressed compassion, empathy, and kindness may overcome other issues and create an overall positive experience.
Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , Biological Products/therapeutic use , Melanoma/drug therapy , Skin Neoplasms/drug therapy , Antineoplastic Agents, Immunological/administration & dosage , Biological Products/administration & dosage , Herpesvirus 1, Human , Humans , Injections, Intralesional , Lymphatic Metastasis , Melanoma/pathology , Neoplasm Staging , Skin Neoplasms/pathologyABSTRACT
Currently, there is no sensitive molecular test for identifying transformation-prone actinic keratoses (AKs) and aggressive squamous cell carcinoma (SCC) subtypes. Biomarker-based molecular testing represents a promising tool for risk stratifying these lesions. We evaluated the utility of a panel of ultraviolet (UV) radiation-biomarker genes in distinguishing between benign and transformation-prone AKs and SCCs. The expression of the UV-biomarker genes in 31 SCC and normal skin (NS) pairs and 10 AK/NS pairs was quantified using the NanoString nCounter system. Biomarker testing models were built using logistic regression models with leave-one-out cross validation in the training set. The best model to classify AKs versus SCCs (area under curve (AUC) 0.814, precision score 0.833, recall 0.714) was constructed using a top-ranked set of 13 UV-biomarker genes. Another model based on a 15-gene panel was developed to differentiate histologically concerning from less concerning SCCs (AUC 1, precision score 1, recall 0.714). Finally, 12 of the UV-biomarker genes were differentially expressed between AKs and SCCs, while 10 genes were uniquely expressed in the more concerning SCCs. UV-biomarker gene subsets demonstrate dynamic utility as molecular tools to classify and risk stratify AK and SCC lesions, which will complement histopathologic diagnosis to guide treatment of high-risk patients.
Subject(s)
Carcinoma, Squamous Cell/genetics , Keratosis, Actinic/genetics , Skin Neoplasms/genetics , Skin/pathology , Aged , Aged, 80 and over , Disease Progression , Female , Genetic Markers , Humans , Male , Middle Aged , Risk Assessment , Ultraviolet Rays/adverse effectsABSTRACT
Patients awaiting lung transplantation face high wait-list mortality, as injury precludes the use of most donor lungs. Although ex vivo lung perfusion (EVLP) is able to recover marginal quality donor lungs, extension of normothermic support beyond 6 h has been challenging. Here we demonstrate that acutely injured human lungs declined for transplantation, including a lung that failed to recover on EVLP, can be recovered by cross-circulation of whole blood between explanted human lungs and a Yorkshire swine. This xenogeneic platform provided explanted human lungs a supportive, physiologic milieu and systemic regulation that resulted in functional and histological recovery after 24 h of normothermic support. Our findings suggest that cross-circulation can serve as a complementary approach to clinical EVLP to recover injured donor lungs that could not otherwise be utilized for transplantation, as well as a translational research platform for immunomodulation and advanced organ bioengineering.
Subject(s)
Acute Lung Injury/therapy , Lung Transplantation/methods , Lung/blood supply , Organ Preservation/methods , Acute Lung Injury/blood , Acute Lung Injury/physiopathology , Animals , Extracorporeal Circulation/methods , Humans , Lung/physiopathology , Perfusion/methods , Swine , Tissue DonorsABSTRACT
The signal transducer and activator of transcription 6 (STAT6) is a critical up-stream mediator of interleukin-13 (IL-13) and IL-4 signaling and is constitutively activated in malignant lymphocytes from Sezary syndrome (SS) and mycosis fungoides (MF), the most common subtypes of cutaneous T-cell lymphomas. By combining genome-wide expression profiling with pharmacological STAT6 inhibition, we have identified the genes regulated by STAT6 in MF/SS tumors. We found that STAT6 regulates several common pathways in MF/SS malignant lymphocytes that are associated with control of cell-cycle progression and genomic stability as well as production of Th2 cytokines. Using ex vivo skin explants from cutaneous MF tumors as well as Sezary cells derived from the blood of SS patients, we demonstrated that inhibition of STAT6 activation downregulates cytokine production and induces cell-cycle arrest in MF/SS malignant lymphocytes, inhibiting their proliferation but not their survival. Furthermore, we show that STAT6 promotes the protumoral M2-like phenotype of tumor-associated macrophages in the tumor microenvironment of advanced stage MF by upregulating the expression of genes associated with immunosuppression, chemotaxis, and tumor matrix remodeling. Thus, we show STAT6 to be a major factor in the pathogenesis and progression of MF/SS, promoting proliferation and invasion of the malignant lymphocytes while inducing a progressive depression of the antitumor immune response. Together, our results provide new insights into disease pathogenesis and offer new prospective targets for therapeutic intervention.
Subject(s)
Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Lymphoma, T-Cell, Cutaneous/genetics , Lymphoma, T-Cell, Cutaneous/metabolism , STAT6 Transcription Factor/metabolism , Transcriptome , Biomarkers, Tumor , Cell Cycle/genetics , Genome-Wide Association Study , Humans , Lymphoma, T-Cell, Cutaneous/immunology , Lymphoma, T-Cell, Cutaneous/pathology , Neoplasm Metastasis , Neoplasm Staging , Tumor Microenvironment/genetics , Tumor Microenvironment/immunology , Tumor-Associated Macrophages/immunology , Tumor-Associated Macrophages/metabolism , Tumor-Associated Macrophages/pathologyABSTRACT
Canonical ultraviolet (UV) mutation type and spectra are traditionally defined by direct sequencing-based approaches to map mutations in a limited number of representative DNA elements. To obtain an unbiased view of genome wide UV mutation features, we performed whole exome-sequencing (WES) to profile single nucleotide substitutions in UVB-irradiated primary human keratinocytes. Cross comparison of UV mutation profiles under different UVB radiation conditions revealed that T > C transition was highly prevalent in addition to C > T transition. We also identified 5'-ACG-3' as a common sequence motif of C > T transition. Furthermore, our analyses uncovered several recurring UV mutations following acute UVB radiation affecting multiple genes including HRNR, TRIOBP, KCNJ12, and KMT2C, which are frequently mutated in skin cancers, indicating their potential role as founding mutations in UV-induced skin tumorigenesis. Pretreatment with trichostatin A, a pan-histone deacetylase inhibitor that renders chromatin decondensation, significantly decreased the number of mutations in UVB-irradiated keratinocytes. Unexpectedly, we found trichostatin A to be a mutagen that caused DNA damage and mutagenesis at least partly through increased reactive oxidation. In summary, our study reveals new UV mutation features following acute UVB radiation and identifies novel UV mutation hotspots that may potentially represent founding driver mutations in skin cancer development.
Subject(s)
Exome Sequencing , Hydroxamic Acids/pharmacology , Keratinocytes/drug effects , Keratinocytes/metabolism , Keratinocytes/radiation effects , Mutation , Ultraviolet Rays , Computational Biology/methods , DNA Damage , Genomic Instability , Humans , Polymorphism, Single Nucleotide , Protein Synthesis Inhibitors/pharmacologyABSTRACT
Skin cancer affects 1 in 5 Americans, resulting in significant morbidity and mortality. Treatment costs and rates of skin cancer and melanoma continue to rise, making preventative measures increasingly important. However, there is conflicting evidence about efficacy of primary and secondary prevention strategies in decreasing incidence and improving early diagnosis. The US Preventative Services Task Force 2016 guidelines did not endorse routine skin cancer screening because of "insufficient evidence." Yet, countries like Australia have shown the feasibility and cost-effectiveness of primary sun safety interventions and secondary prevention measures such as routine skin cancer surveillance. Additional emerging evidence shows that regular skin cancer screening in high-risk populations improves early detection and decreases melanoma mortality. New technology may enhance prevention, promote accurate diagnoses, and improve management of melanoma and nonmelanoma skin cancers. Here, we place rising rates of melanoma within historical context, review costs, efficacy, and evidence for primary and secondary skin cancer prevention and examine the evolving role of novel technologies in the field.
Subject(s)
Melanoma/diagnosis , Melanoma/prevention & control , Skin Neoplasms/diagnosis , Skin Neoplasms/prevention & control , Early Detection of Cancer , Humans , Melanoma/epidemiology , Skin Neoplasms/epidemiologyABSTRACT
OBJECTIVES: Lung remains the least-utilized solid organ for transplantation. Efforts to recover donor lungs with reversible injuries using ex vivo perfusion systems are limited to <24 hours of support. Here, we demonstrate the feasibility of extending normothermic extracorporeal lung support to 4 days using cross-circulation with conscious swine. METHODS: A swine behavioral training program and custom enclosure were developed to enable multiday cross-circulation between extracorporeal lungs and recipient swine. Lungs were ventilated and perfused in a normothermic chamber for 4 days. Longitudinal analyses of extracorporeal lungs (ie, functional assessments, multiscale imaging, cytokine quantification, and cellular assays) and recipient swine (eg, vital signs and blood and tissue analyses) were performed. RESULTS: Throughout 4 days of normothermic support, extracorporeal lung function was maintained (arterial oxygen tension/inspired oxygen fraction >400 mm Hg; compliance >20 mL/cm H2O), and recipient swine were hemodynamically stable (lactate <3 mmol/L; pH, 7.42 ± 0.05). Radiography revealed well-aerated lower lobes and consolidation in upper lobes of extracorporeal lungs, and bronchoscopy showed healthy airways without edema or secretions. In bronchoalveolar lavage fluid, granulocyte-macrophage colony-stimulating factor, interleukin (IL) 4, IL-6, and IL-10 levels increased less than 6-fold, whereas interferon gamma, IL-1α, IL-1ß, IL-1ra, IL-2, IL-8, IL-12, IL-18, and tumor necrosis factor alpha levels decreased from baseline to day 4. Histologic evaluations confirmed an intact blood-gas barrier and outstanding preservation of airway and alveolar architecture. Cellular viability and metabolism in extracorporeal lungs were confirmed after 4 days. CONCLUSIONS: We demonstrate feasibility of normothermic maintenance of extracorporeal lungs for 4 days by cross-circulation with conscious swine. Cross-circulation approaches could support the recovery of damaged lungs and enable organ bioengineering to improve transplant outcomes.
Subject(s)
Extracorporeal Circulation/methods , Lung Transplantation/methods , Organ Preservation/methods , Animals , Models, Animal , Swine , Time FactorsSubject(s)
Biological Products/administration & dosage , Injections, Intralesional/standards , Melanoma/therapy , Oncolytic Virotherapy/methods , Skin Neoplasms/therapy , Biological Products/adverse effects , Dose-Response Relationship, Drug , Drug Administration Schedule , Herpesvirus 1, Human , Humans , Injections, Intralesional/instrumentation , Melanoma/diagnosis , Melanoma/pathology , Neoplasm Staging/methods , Oncolytic Virotherapy/adverse effects , Oncolytic Virotherapy/instrumentation , Oncolytic Virotherapy/standards , Patient Selection , Practice Guidelines as Topic , Skin/diagnostic imaging , Skin/pathology , Skin Neoplasms/diagnosis , Skin Neoplasms/pathology , Ultrasonography, InterventionalABSTRACT
Cutaneous metastases from hepatocellular carcinoma (HCC) are extremely rare and can represent a sign of an underlying malignancy or relapse/progression from an existing tumor. We report a case of a cutaneous metastasis arising in a patient with metastatic HCC following orthotopic liver transplantation. Diagnosis is a multistep process as cutaneous HCC metastases must be differentiated from primary cutaneous malignancies as well as other cutaneous metastases. Making this even more challenging, HCC metastases have heterogeneous clinical and histologic appearances. Therefore, the use of immunohistochemical stains, including hepatocyte paraffin-1, arginase-1, and glypican-3, and correlation with the clinical context are essential for a correct diagnosis.
Subject(s)
Carcinoma, Hepatocellular , Facial Neoplasms , Liver Neoplasms , Liver Transplantation , Neoplasm Proteins/metabolism , Skin Neoplasms , Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/pathology , Facial Neoplasms/metabolism , Facial Neoplasms/pathology , Facial Neoplasms/secondary , Fibrosis/surgery , Humans , Liver Neoplasms/metabolism , Liver Neoplasms/pathology , Male , Middle Aged , Neoplasm Metastasis , Skin Neoplasms/metabolism , Skin Neoplasms/pathology , Skin Neoplasms/secondaryABSTRACT
The IL-36 subfamily of cytokines belongs to the IL-1 superfamily and consists of three pro-inflammatory agonists IL-36α, IL-36ß, IL-36γ, and an IL-36 receptor (IL-36R) antagonist, IL-36Ra. These IL-36 cytokines function through a common receptor to modulate innate and adaptive immune responses. IL-36 cytokines are expressed as inactive precursors and require proteolytic processing to become fully active. Upon binding to IL-36R, IL-36 agonists augment the expression and production of inflammatory cytokines via activating signaling pathways. IL-36 is mainly expressed in epidermal, bronchial, and intestinal epithelial cells that form the barrier structures of the body and regulates the balance between pro-inflammatory and anti-inflammatory cytokine production at these tissue sites. Dysregulation of IL-36 signaling is a major etiological factor in the development of autoimmune and inflammatory diseases. Besides its critical role in inflammatory skin diseases such as psoriasis, emerging evidence suggests that aberrant IL-36 activities also promote inflammatory diseases in the lung, kidneys, and intestines, underscoring the potential of IL-36 as a therapeutic target for common inflammatory diseases. The role of IL-36 signaling in cancer development is also under investigation, with limited studies suggesting a potential anti-tumor effect. In this comprehensive review, we summarize current knowledge regarding the expression, activation, regulatory mechanisms, and biological functions of IL-36 signaling in immunity, inflammatory diseases, and cancer development.